NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX
Post# of 145
(Total Views: 39)
Posted On: 10/01/2025 5:30:56 PM
NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Closes $7.5 Million Public Offering to Extend Cash Runway Through 2026
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the closing of its $7.5 million public offering of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with proceeds intended to fund R&D, commercialization, working capital, and general corporate purposes; the financing, which included participation from existing and institutional healthcare investors, also amends prior warrants to a $1.35 exercise price and extends the company’s cash runway through the end of 2026.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the closing of its $7.5 million public offering of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with proceeds intended to fund R&D, commercialization, working capital, and general corporate purposes; the financing, which included participation from existing and institutional healthcare investors, also amends prior warrants to a $1.35 exercise price and extends the company’s cash runway through the end of 2026.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://nnw.fm/SNGX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)